MAPT and Alzheimer disease: Furthermore, the observed association between cerebrovascular dysfunction and reduced cerebral glucose metabolism, increased amyloid burden and elevated neurodegenerative biomarkers (p-tau, neurofilament light chain, GFAP) [3], strongly suggests a central role for cerebrovascular impairment, either independently or synergistically with amyloid and tau pathologies, in the initiation and progression of AD.